← All trials
NCT06632236
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2024
- Primary completion
- Mar 5, 2026
- Completion date
- Mar 5, 2027
- First posted
- Oct 9, 2024
- Last posted
- Nov 6, 2024
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- University of CambridgeCollaborator
- University of CambridgeCollaborator
- Janssen Pharmaceutica NVCollaborator
- Royal Marsden Hospital NHS TrustCollaborator
- Minderoo FoundationCollaborator
- Cancer Research UKCollaborator
- National Health Service, United KingdomOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.